In 2018, the market for protein binding assays was worth USD 304.7 million. It is expected to grow at 10.6% CAGR over the forecast period. The protein binding assay is essential for drug development preclinical processes. Many pharmaceutical and biotech companies are taking initiatives to meet the increasing demand for advanced therapies. This will help boost drug discovery and development.
U.S. FDA reported that 59 new therapeutics and biologics were approved in 2018 by Center for Drug Evaluation and Research (CDER), compared with 46 new drugs in 2017. The increase in drug candidates being approved and screened annually drives the adoption protein binding assays.
Preclinical screening is an investment by pharmaceutical companies to prevent late-stage failures in the development of therapeutics. According to estimates, preclinical testing was the most popular activity in pharmaceutical companies in June 2018.
Drug discovery and development is expensive. It requires high capital investments, technological capabilities and human resources. Manufacturers can lose a lot of money if a drug candidate fails to develop during development. By analyzing the binding and absorption abilities of protein binding assays in preclinical stages, drug discovery costs can be optimized. This helps reduce drug attrition during late stages.
In situ protein-protein interaction assays, which are more sensitive than traditional techniques, are expected to increase the adoption of these assays. This market will also benefit from parallel testing to analyze assays that are used for determining the potency.
Equilibrium dialysis has been deemed the gold standard in evaluating drug-protein binding. The large segment can boast many advantages, including high accuracy, reliability and low cost.
It is easy to use equilibrium dialysis for determining the protein binding ability of a compound. Ultrafiltration was able to generate a significant revenue share due to its widespread implementation as a high throughput method for determining the binding ability of unstable compounds and their plasma unbound fraction. Ultrafiltration is limited by the non-specific binding of compounds to filter membranes or collection chambers.
Both of the above-mentioned methods are suitable for high hydrophilic drugs, and have high adoption rates. Ultracentrifugation is less popular than the other two methods due to their slower processing times and higher costs.
Numerous key players and CROs offer protein binding services. This is what contributed to the high revenue share of this segment in 2018. Many companies are involved in the provision of services for protein binding assays, including Eurofins Scientific, Cyprotex, Charles River Laboratories, Sekisui XenoTech, LLC, and others.
The Instruments segment is expected to grow rapidly due to the availability of automated systems to detect protein binding and user-friendly instruments. Rapid Equilibrium Dialysis by Thermo Fisher, for example, is convenient for radioactive material laboratories because it uses disposable inserts and a base plate.
The dominant revenue segment was pharmaceutical and biotechnology companies in 2018. Because companies hold a large share of global pharma production, and make significant investments in preclinical testing stages for drug discovery, this is why they are the dominant segment in 2018. This industry is characterized by large, established players like Roche and Merck, which are actively involved in enhancing their R&D activities to preserve their market position.
To capitalize on the opportunities in the biopharmaceutical sector, a large number of CROs that are focused on developing therapeutics have entered the market. The cost advantages associated with outsourcing pharmaceutical manufacturing as well as quality control steps are driving the increase in demand for CROs. These factors are driving revenue generation in the CROs segment.
North America held the largest share of the protein binding assays industry, with a major contribution from the U.S. Research activities in the area of drug discovery are encouraged by the availability of grants from government agencies like the National Institute of Health or the Defense Advanced Research Projects Agency.
Asia Pacific is expected to experience the fastest growth during the forecast period. This is due to numerous initiatives taken by regulatory agencies to transform drug discovery and development programs in the region. Regional growth is also supported by a number of conferences related to pharma research such as the 20th Asia Pacific Pharma Congress, held in April 2019, in Japan.
Many pharmaceutical companies prefer emerging economies in the Asia Pacific region because of their large patient base, operational efficiency, and low cost of developing therapeutics.
The market is dominated by Thermo Fisher Scientific, Inc., Charles River, Sovicell GMBH, Absorption Systems LLC, GE Healthcare, Eurofins Scientific, 3B Pharmaceuticals, Creative Biolabs, Evotec (Cyprotex), and Bioduro. Market players are taking strategic initiatives to expand their market presence and strengthen their protein binding assays portfolio. Some strategies include collaboration models, product development, business expansion and agreements.
In March 2018, Thermo Fisher and Montreal Neurological Institute signed an agreement. The institute created cell lines using Fisher's antibodies, protein binding assays, and used them to study neurodegenerative disorders. Charles River also signed an agreement in February 2019 to acquire Citoxlab in order to increase its market share in the area of drug discovery and development.
This report provides a forecast of revenue growth at the country and regional levels. It also analyzes industry trends for each sub-segment from 2015 to 2026. Grand View Research segmented this report on protein binding assays market based on technology and product & service, region, and end use.
Technology Outlook (Revenue USD Million, 2015-2026)
Ultracentrifugation
Equilibrium Dialysis
Ultrafiltration
Resonance of Surface Plasmon
Other technologies
Product & Services Outlook (Revenue USD Million, 2015 – 2026).
Instrument
Kits and Reagents
Services
End-use Outlook (Revenue USD Million, 2015-2026)
Contract Research Organizations
Companies in Pharmaceutical & Biotechnology
Other End-Use
Regional Outlook (Revenue USD Million, 2015-2026)
North America
The U.S.
Canada
Europe
Germany
The U.K.
Asia Pacific
Japan
China
Latin America
Brazil
Middle East Africa
South Africa
b. Global protein binding assays market was valued at USD 340.2 Million in 2019, and is forecast to grow to USD 379.0 in 2020.
What market growth is expected for protein binding assays?b. Global protein binding assays market will grow at a compound annual rate of 10.5% between 2020 and 2026, to reach USD 682 million by 2026.
Which market segment had the largest share of protein binding assays?b. With a 49.3% share in 2019, Equilibrium Dialysis was the dominant market for protein binding assays. It is the standard for evaluating drug-protein interaction. Equilibrium dialysis has many advantages, including high accuracy, reliability and low cost.
Which companies/players are key players in the protein binding assays marketb. Thermo Fisher Scientific, Inc., Charles River, Sovicell GMBH, Absorption Systems LLC, GE Healthcare, Eurofins Scientific, 3B Pharmaceuticals, Creative Biolabs, Evotec (Cyprotex), and Bioduro are some of the key players in the market for protein binding assays.
What are the main factors that drive the market for protein binding assays?b. The market growth is being driven by several key factors, including an increase in the use of protein binding assays for drug discovery and development, high rates of late-stage drug failure, a large number of CROs working in this space, and significant market share.
Up Market Research published a new report titled “Protein Binding Assays Market research report which is segmented by Services (Instruments), by End Use (Pharmaceutical & Biotechnology Companies), by Technology (Equilibrium Dialysis), By Players/Companies collaborative models, business expansion, Inc; Charles River; Sovicell GMBH; Absorption Systems LLC; GE Healthcare; Eurofins Scientific; 3B Pharmaceuticals; Creative Biolabs; Evotec (Cyprotex); and Bioduro Market players are undertaking several strategic initiatives to strengthen protein binding assays portfolio and increase their footprint in the market Some of the strategies implemented include agreements, Thermo Fisher Scientific, product developments”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Attributes | Report Details |
Report Title | Protein Binding Assays Market Research Report |
By Services | Instruments |
By End Use | Pharmaceutical & Biotechnology Companies |
By Technology | Equilibrium Dialysis |
By Companies | collaborative models, business expansion, Inc; Charles River; Sovicell GMBH; Absorption Systems LLC; GE Healthcare; Eurofins Scientific; 3B Pharmaceuticals; Creative Biolabs; Evotec (Cyprotex); and Bioduro Market players are undertaking several strategic initiatives to strengthen protein binding assays portfolio and increase their footprint in the market Some of the strategies implemented include agreements, Thermo Fisher Scientific, product developments |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 231 |
Number of Tables & Figures | 162 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Services (Instruments), by End Use (Pharmaceutical & Biotechnology Companies), by Technology (Equilibrium Dialysis).
Protein Binding Assays Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Protein Binding Assays Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Protein Binding Assays Market Report:
Some other reports from this category!